로딩 중…
StockDiggingStockDigging

GREEN LIFESCIENCE CO., LTD.

114450· KOSDAQ
₩1,998-7.71%
2026-06-19

Price Chart

GREEN LIFESCIENCE CO., LTD.-44.81%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap39.96B KRW
Revenue51.02B KRW
Net Income729.5M KRW
Total Assets56.01B KRW
Net Assets40.04B KRW
Employees65
Value
P/E54.78x
P/B1.00x
PEG0.29x
P/S0.78x
EV/EBITDA11.96x
FCF Yield-1.24%
Profitability
ROE1.82%
ROA1.30%
Op. Margin5.68%
Revenue Growth219.16%
Earnings Growth187.40%
Financial Health
Debt Ratio139.89%
Total Debt4.80B KRW
FCF-495.7M KRW
Cash10.12B KRW
Current Ratio2.17x
Net Debt/EBITDA-1.83x
Dividend
Div. Growth0.00%
Performance
1Y Return-44.81%
1M Return-33.40%
From 52W High-56.47%
1Y MDD-50.61%
Trading
Volume403,108 shares
Foreign Own.4.79%
Per Share
EPS151 KRW
BPS2,019 KRW

Company Info

CEO 양준화, 이기성(각자 대표이사)
Employees 65
Founded 2005
HQ 전라남도 여수시, KR

Green Life Science, established in 2005 and headquartered in Yeosu-si, Jeollanam-do, is a specialized manufacturer of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, listed on the KOSDAQ market in 2009. The company pioneered the development of EDP-CL, a piperacillin-based antibiotic intermediate, in Korea, supplying it to global pharmaceutical companies, and its synthesis plant was the first in Korea to receive U.S. FDA approval. It produces various APIs and raw material intermediates, including DSC for HIV treatment and antibiotic intermediate AM19, while maintaining a quality management system compliant with cGMP standards.